How to Choose an Independent Clinical Expert for Your EU Dossier
Written byNeta Kela, PhDFounder & Managing Partner
Short answer: Article 12 of Directive 2001/83/EC requires that the Clinical and Nonclinical Overviews are drawn up and signed by experts with the necessary technical or professional qualifications, and that a brief CV is included. When you appoint an expert, you are choosing the person who will be accountable for the critical assessment of your data. Look for relevant scientific depth, the ability to argue benefit-risk, availability through agency questions, and a CV that will stand up to assessor scrutiny.
What does Article 12 require?
The applicant must ensure that the detailed summaries and overviews (Module 2) are drawn up and signed by experts with the necessary qualifications before they are submitted. The expert's CV is included, and the expert's professional relationship with the applicant must be declared. In practice, this means three documents: the signed overview, the expert's signature page and statement, and the CV in Module 1.
Why the choice matters
The Clinical Overview is not a summary of Module 5. It is the expert's critical assessment of whether the evidence supports the proposed indication and benefit-risk conclusion. If the assessment is weak, the dossier is weak, however good the underlying data. Assessors read the overview first, and the expert's name is on it.
What to look for
- Relevant scientific background. A drug development or clinical pharmacology background in the product class matters more than writing volume.
- Experience with your legal basis. Hybrid and well-established use files need someone who can build a scientific argument with partial data, not only describe a full development program.
- Independence and clear accountability. One named expert who personally signs, not a writing team behind an anonymous signature.
- Availability after submission. The expert should support responses to the list of questions, because the answers must stay consistent with the overview.
- Both overviews in one view. Where the same expert covers Clinical (2.5) and Nonclinical (2.4), the assessment is consistent across modules.
Questions to ask before appointing an expert
- Which dossier types and legal bases have you assessed or signed?
- Will you personally write the critical assessment, or review someone else's draft?
- How do you handle data gaps you identify during drafting?
- Will you support us through Day 120 and Day 180 questions?
- Can you update the overviews for later variations?
Sources
- EMA: Pre-authorisation guidance: https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/pre-authorisation-guidance
- EUPATI: Marketing authorisation applications: https://toolbox.eupati.eu/resources/marketing-authorisation-applications/
- EMA: Generic and hybrid applications: https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/generic-hybrid-medicines/generic-hybrid-applications
Frequently Asked Questions
How PXM Helps With This
Related
Part of FDA & CMC Readiness. Start from the pillar: Operate practice, FDA Regulatory Readiness, CMC & Manufacturing, FDA Expedited Pathways, EU Regulatory Pathways
What a Clinical Overview Must Contain for an EU Hybrid Application
What the Clinical Overview (Module 2.5) must cover in an EU hybrid application under Article 10(3), how to justify differences from the reference product, and where assessors push back.
Well-Established Use Applications: Building a Bibliographic Clinical Overview That Holds Up
How to build the Clinical Overview for an EU well-established use application under Article 10a: the ten-year test, literature selection, and how to bridge your product to the published evidence.
FDA National Priority Voucher (CNPV): Should You Apply?
What the FDA national priority voucher (CNPV) offers in 2026, how it compares to other expedited programs, and what EU sponsors need ready first.
Get notified when we publish new funding and regulatory guides
Practical guidance on FDA and EMA strategy, CMC readiness, and non-dilutive funding — sent only when there is something worth reading.